Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013
Adam Meijer, Helena Rebelo-de-Andrade, Vanessa Correia, Terry Besselaar, Renu Drager-Dayal, Alicia Fry, Vicky Gregory, Larisa Gubareva, Tsutomu Kageyama, Angie Lackenby, Janice Lo, Takato Odagiri, Dmitriy Pereyaslov, Marilda M Siqueira, Emi Takashita, Masato Tashiro, Dayan Wang, Sun Wong, Wenqing Zhang, Rod S Daniels Show all
Antiviral Research | ELSEVIER SCIENCE BV | Published : 2014
Awarded by British Medical Research Council
We thank all laboratories, mostly NICs of the WHO GISRS (http://www.who.int/influenza/gisrs_laboratory/national_influenza_centres/list/en/), which contributed to this global analysis by submitting influenza virus positive samples (clinical specimens or virus isolates) to WHO CCs for detailed characterisation. We gratefully acknowledge the authors, originating and submitting laboratories of the 372 sequences unique to the GISAID database, additional to those of the 2826 sequences submitted to the GISAID database by the authors of this paper and the 233 sequences imported by GISAID from public databases (Supplementary Table 3), and the 230 sequences retrieved from NCBI-IVR, that were included in this global analysis. The London WHO CC is funded by the British Medical Research Council through programme U117512723. The Melbourne WHO CC is supported by the Australian Government, Department of Health. The Tokyo WHO CC is supported by Grants-in-Aid for Emerging and Re-emerging Infectious Diseases from the Ministry of Health, Labour and Welfare, Japan - Japan.